United States Patent 7,671,094: Bupropion Hydrobromide Claims, Exclusivity, Litigation Risk, and Patent Landscape

U.S. Patent 7,671,094 protects compositions and treatment methods using bupropion hydrobromide, particularly modified-release tablets intended to reduce bupropion-induced seizure risk relative to an equivalent molar dose of bupropion hydrochloride. The patent covers both product configurations and therapeutic use. Its most commercially relevant claims are directed to bupropion hydrobromide tablets containing 174 mg, 348 mg, or 522 mg of the salt, corresponding approximately to 150 mg, 300 mg, and 450 mg of bupropion base.

The patent is associated with Aplenzin, an extended-release bupropion hydrobromide product approved by the U.S. Food and Drug Administration. The Orange Book lists U.S. Patent 7,671,094 for Aplenzin with an expiration date of February 7, 2026.[1,2]

What patent protects bupropion hydrobromide and Aplenzin?

U.S. Patent 7,671,094 is titled “Bupropion hydrobromide compositions and methods of use thereof.” The patent claims the use of the hydrobromide salt rather than the more established bupropion hydrochloride salt.

Field	Patent 7,671,094
U.S. patent	7,671,094
Grant date	March 2, 2010
Active pharmaceutical ingredient	Bupropion hydrobromide
Comparator	Equivalent molar amount of bupropion hydrochloride
Principal dosage form	Tablet
Key formulation	Modified-release or controlled-release tablet
Express dose amounts	174 mg, 348 mg, and 522 mg bupropion hydrobromide
Key safety endpoint	Incidence and severity of bupropion-induced seizures
Measurement method	EEG using a hippocampally implanted depth electrode
Listed Orange Book expiration	February 7, 2026
Commercial product associated with the patent	Aplenzin extended-release tablets

The patent does not claim bupropion generally. It claims a particular salt form, formulations containing that salt, and methods of administering it to reduce or manage seizure-related risk.

What are the independent claims of Patent 7,671,094?

The independent claims are claims 1, 6, 7, 13, 15, and 16. They divide into three groups.

Composition claims

Claims 1, 6, and 16 require a composition containing:

Bupropion hydrobromide;
At least one pharmaceutically acceptable excipient; and
A comparative seizure result against bupropion hydrochloride.

Claim 1 requires the comparative result to be shown in rats through electroencephalogram analysis using a hippocampally implanted depth electrode. Claim 6 narrows the test to administration of approximately 100 mg/kg. Claim 16 applies the 100 mg/kg comparative condition to the bupropion hydrobromide used to manufacture the composition.

These are not conventional composition claims limited only by ingredients. They include a functional or product-characterization limitation based on an in vivo comparative result.

Treatment-method claims

Claim 7 covers treating a subject at risk of bupropion-induced seizures by administering bupropion hydrobromide in an amount sufficient to treat the subject.

Claim 13 covers reducing the incidence of bupropion-induced seizures by administering a pharmaceutically effective amount of bupropion hydrobromide. Claim 14 adds the limitation that the seizures are less severe than those resulting from an equivalent molar amount of bupropion hydrochloride.

Claim 15 narrows the method to approximately 100 mg/kg in rats and requires EEG measurement with a hippocampally implanted depth electrode.

Dependent formulation claims

Claims 2 through 5 and 8 through 12 add narrower limitations:

Tablet dosage form;
Modified-release formulation;
Core tablet containing bupropion hydrobromide;
Coating over the core;
Controlled-release coating;
Oral administration; and
174 mg, 348 mg, or 522 mg of bupropion hydrobromide.

These dependent claims create separate infringement positions for extended-release tablets even if a broader claim is challenged.

How broad is the scope of Patent 7,671,094?

The patent has a mixed scope. The salt and therapeutic concept are broad, but several claims contain technical limitations that may restrict enforcement.

Broadest practical composition scope

Claim 1 is broad in dosage-form terms. It does not require a tablet, modified release, or a particular dose. A composition containing bupropion hydrobromide and an excipient could fall within the claim if the required comparative seizure result is established.

The claim covers immediate-release and modified-release compositions unless another limitation excludes them. Claims 2 through 5 then narrow the scope to tablets and coated or controlled-release tablets.

Broadest practical method scope

Claim 7 is potentially the broadest treatment claim because it does not expressly require:

A comparative result against bupropion hydrochloride;
A particular dose;
A tablet;
Modified release;
Oral administration; or
EEG testing.

It requires administration of bupropion hydrobromide to a subject at risk of bupropion-induced seizures who needs bupropion treatment.

Claims 13 and 14 are narrower because they require a seizure-reduction result relative to bupropion hydrochloride. Claim 15 is narrower still because it specifies rat testing, a 100 mg/kg dose, and hippocampal-depth-electrode EEG.

Key claim-construction issues

Claim term or limitation	Potential legal significance
“Bupropion hydrobromide”	Requires the hydrobromide salt, not bupropion hydrochloride or an unprotonated form
“Equivalent molar amount”	Requires dose normalization based on moles of bupropion or salt
“Less incidences”	May be construed as fewer seizure events, although the wording is grammatically imprecise
“Less severe”	Requires a comparative severity assessment
“About 100 mg/kg”	Creates a dose range subject to ordinary claim-construction principles
“At risk of bupropion-induced seizures”	May require evidence that the treated subject has a clinically relevant seizure risk
“Sufficient to treat”	Functional treatment limitation tied to the claimed indication
“Modified release”	Captures formulations that alter release relative to immediate release
“Controlled-release coating”	Requires the coating to control drug release, not merely protect the tablet
“Hippocampally implanted depth electrode”	Narrows the specified animal-study claims to a particular EEG methodology

The rat EEG limitations are especially important. They may be useful to establish written description and enablement for the comparative seizure-safety theory, but they can also limit direct infringement allegations against products that have not been tested using that exact protocol.

What formulations are protected by Patent 7,671,094?

The patent protects more than the chemical identity of bupropion hydrobromide. The dependent claims specifically cover tablet architecture.

Core-and-coating formulations

Claims 4 and 11 require bupropion hydrobromide to be contained in a tablet core with a coating over the core. Claims 5 and 12 further require a controlled-release coating.

A formulation may face risk if it contains:

A bupropion hydrobromide core;
A polymeric or otherwise release-controlling coating;
A coated matrix or reservoir structure; and
An oral modified-release presentation.

The claims do not appear, from the supplied claim language, to require a particular polymer, coating thickness, dissolution profile, tablet hardness, or manufacturing process. Those parameters could matter in claim construction, infringement testing, and validity analysis, but they are not express limitations in the quoted claims.

Dose-specific protection

The amounts in claims 8 and the related formulation claims are salt amounts:

Bupropion hydrobromide	Approximate bupropion base equivalent
174 mg	150 mg
348 mg	300 mg
522 mg	450 mg

The conversion reflects the molecular-weight difference between bupropion hydrobromide and bupropion hydrochloride. A product labeled by bupropion-base equivalent could still implicate the claims if the actual salt amount falls within the claimed amounts.

When does Patent 7,671,094 lose exclusivity?

The Orange Book lists February 7, 2026, as the patent expiration date for Aplenzin.[1] The date is the principal U.S. patent barrier identified for the bupropion hydrobromide product.

Milestone	Date or status
Patent grant	March 2, 2010
FDA approval of Aplenzin	2008
Orange Book patent listing	U.S. 7,671,094
Listed patent expiration	February 7, 2026
Small-molecule regulatory pathway	ANDA under Hatch-Waxman
Biosimilar pathway	Not applicable

The effective market-exclusivity analysis must separate patent expiration from FDA regulatory exclusivity. Aplenzin is a small-molecule drug, so biosimilar rules do not apply. A generic applicant would normally use an ANDA, with a Paragraph IV certification if seeking approval before patent expiration.

What is the Orange Book status of bupropion hydrobromide?

Aplenzin is an FDA-approved extended-release bupropion hydrobromide product. The product’s clinical and regulatory distinction from Wellbutrin XL is the salt form: Aplenzin uses bupropion hydrobromide, while Wellbutrin products use bupropion hydrochloride.

The Orange Book listing is relevant because it gives an ANDA applicant notice of the listed patent and creates the framework for a Paragraph IV challenge. The listing does not itself establish that every bupropion hydrobromide product infringes every claim. Infringement depends on the product’s formulation, labeling, use, and the construction of the comparative limitations.[1,3]

Which companies are challenging Patent 7,671,094?

The FDA Orange Book entry identifies the listed patent but is not a complete database of Paragraph IV litigation or settlement agreements. The supplied patent and FDA materials do not establish a reported Paragraph IV judgment, consent judgment, or settlement involving U.S. Patent 7,671,094.

A generic applicant could challenge the patent through:

Paragraph IV certification;
Declaratory judgment litigation;
Invalidity arguments under Sections 102, 103, and 112;
Noninfringement arguments based on salt, formulation, or labeling differences; or
A post-grant or inter partes review strategy, subject to statutory timing and available grounds.

The most credible validity theories would focus on obviousness of selecting the hydrobromide salt, enablement of the seizure-reduction result across the claimed composition scope, indefiniteness of comparative terms, and written-description support for broad treatment claims.

What generic entry risks exist for Aplenzin?

Generic entry risk is concentrated in three periods.

Before February 2026

A Paragraph IV applicant could seek approval before the listed expiration date. The principal defenses would likely be noninfringement and invalidity. A product using bupropion hydrochloride instead of bupropion hydrobromide would not ordinarily practice the salt limitation literally, although the doctrine of equivalents could become relevant depending on the claim and prosecution history.

A product using bupropion hydrobromide but avoiding the claimed controlled-release structure could still face risk under claims 1, 6, 7, 13, or 16.

At patent expiration

After February 7, 2026, the patent should no longer block approval based solely on its listed term, absent a valid patent-term adjustment, pediatric extension, injunction, or another separately enforceable patent.

After expiration

The principal commercial barriers would shift from patent exclusivity to:

Manufacturing scale-up;
Bioequivalence for extended-release delivery;
Salt-form control;
Dissolution-profile matching;
Stability and impurity specifications;
FDA approval timing; and
Market access and substitution.

The product-specific seizure-safety claims could still complicate formulation design, but expired patent claims do not prevent launch.

How strong is the patent estate for bupropion hydrobromide?

The estate appears narrow in number but meaningful in product relevance. Based on the cited Orange Book materials, U.S. Patent 7,671,094 is the principal listed U.S. patent associated with Aplenzin.[1]

Strength factor	Assessment
Salt-form differentiation	Strong product-identification limitation
Broad composition coverage	Moderate, because claims require comparative functional results
Modified-release coverage	Meaningful for Aplenzin-type tablets
Dose-specific coverage	Stronger for 174 mg, 348 mg, and 522 mg products
Method-of-use coverage	Potentially broad under claim 7
Comparative seizure limitation	Creates proof and construction issues
Manufacturing-process coverage	Limited in the quoted claims
Patent count	Concentrated rather than layered
Biosimilar protection	Not applicable
Post-expiration barrier	Primarily regulatory and manufacturing

The patent is more valuable as a product-specific barrier than as a broad platform patent covering all bupropion products.

How does Patent 7,671,094 compare with bupropion hydrochloride patents?

Bupropion hydrochloride has an older and broader historical patent and regulatory base. Original bupropion patents and Wellbutrin-related formulation patents addressed the active compound, antidepressant use, and sustained or extended release. Many of those early rights have expired or are no longer the principal barrier to generic bupropion hydrochloride.

Patent 7,671,094 differs in three respects:

It focuses on the hydrobromide salt.
It links the salt to reduced seizure incidence or severity.
It claims specific modified-release tablet configurations.

Issue	Bupropion hydrochloride	Bupropion hydrobromide under Patent 7,671,094
Salt	Hydrochloride	Hydrobromide
Major commercial products	Wellbutrin, Zyban and generics	Aplenzin
Regulatory pathway	Established generic market	Product-specific ANDA opportunity
Core patent theory	Compound, use, and release formulation	Salt, seizure comparison, and formulation
Biosimilar relevance	None	None
Substitution	Not automatically equivalent at the salt level	Requires hydrobromide-specific product development

A generic bupropion hydrochloride product is not automatically a generic substitute for Aplenzin. The active moiety is related, but the salt, dose expression, formulation, labeling, and FDA reference-product requirements differ.

What manufacturing and IP barriers remain?

The patent claims do not expressly recite a particular manufacturing process. They therefore do not create a clear process monopoly over granulation, compression, coating, drying, or packaging based solely on the quoted claims.

Manufacturing risk remains in:

Producing the correct bupropion hydrobromide polymorph or solid form;
Controlling water content and chemical stability;
Achieving reproducible extended-release dissolution;
Coating the tablet uniformly;
Demonstrating bioequivalence; and
Maintaining dose proportionality across 174 mg, 348 mg, and 522 mg strengths.

Separate patents or unpublished applications could affect these areas, but they are not established by the claims supplied or the cited Orange Book entry.

What is the commercial exposure associated with the patent?

The commercial exposure is tied to the Aplenzin franchise rather than the entire bupropion market. Bupropion hydrochloride products such as generic Wellbutrin XL and related products represent a separate, larger market that is not automatically blocked by Patent 7,671,094.

The patent’s economic value depends on:

Aplenzin prescription volume;
The price premium for the hydrobromide product;
Whether FDA permits an ANDA based on Aplenzin;
The timing of any Paragraph IV filing;
The ability of a challenger to design around the coated-tablet claims; and
Whether the sponsor has additional unlisted or later-expiring rights.

No revenue figure is stated here because the patent materials and FDA sources cited do not establish a reliable product-specific revenue amount.

Key Takeaways

U.S. Patent 7,671,094 is the principal cited patent for bupropion hydrobromide products associated with Aplenzin.
The patent covers compositions, modified-release tablets, controlled-release coatings, and methods intended to reduce bupropion-induced seizures.
Claims 1, 6, 15, and 16 rely on comparative rat seizure results measured by hippocampal-depth-electrode EEG.
Claim 7 is potentially the broadest treatment claim because it does not expressly require the comparative rat or EEG limitation.
Claims 8 and related dependent claims protect 174 mg, 348 mg, and 522 mg bupropion hydrobromide strengths.
The Orange Book-listed expiration date is February 7, 2026.
Bupropion hydrochloride generics are not automatically substitutes for bupropion hydrobromide products.
The principal generic strategies are Paragraph IV invalidity, noninfringement based on salt or formulation differences, and post-expiration ANDA launch.
The patent estate is concentrated and product-specific, rather than a broad multi-patent platform.
No Paragraph IV judgment or settlement is established by the cited FDA and patent materials.

FAQs About Patent 7,671,094 and Bupropion Hydrobromide

Is Aplenzin the same drug as Wellbutrin XL?

No. Both deliver bupropion, but Aplenzin uses bupropion hydrobromide and Wellbutrin XL uses bupropion hydrochloride. They are related products with different salt forms and regulatory reference products.

Does a generic bupropion hydrochloride product infringe Patent 7,671,094?

Not ordinarily on a literal basis because the claims require bupropion hydrobromide. Infringement analysis would still depend on claim construction, formulation, labeling, and any doctrine-of-equivalents theory.

Can a generic avoid the patent by using an immediate-release tablet?

Potentially, but not necessarily. Immediate release may avoid dependent modified-release and controlled-coating claims, while broader composition or method claims could remain relevant.

Why do some claims require rat EEG testing?

The EEG limitation defines the comparative seizure endpoint used to distinguish bupropion hydrobromide from bupropion hydrochloride. It may narrow infringement proof but also supplies technical specificity for the claimed safety comparison.

Is there a biosimilar pathway for bupropion hydrobromide?

No. Bupropion is a small-molecule drug. A competing product would generally use the ANDA pathway, not the biologics license application or biosimilar pathway.

References

U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book, Aplenzin entry and patent listing. FDA.
U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,671,094: Bupropion hydrobromide compositions and methods of use thereof. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2008). Aplenzin (bupropion hydrobromide) extended-release tablets prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Drugs@FDA: Aplenzin, NDA 021515. FDA.
Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. §§ 355 and 355(j) (2024).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-001	Apr 23, 2008		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Bausch	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-002	Apr 23, 2008		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Bausch	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-003	Apr 23, 2008		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006261788	⤷ Start Trial
Australia	2008285660	⤷ Start Trial
Australia	2008320915	⤷ Start Trial
Canada	2578626	⤷ Start Trial
Canada	2655596	⤷ Start Trial
Canada	2699588	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,671,094

Which drugs does patent 7,671,094 protect, and when does it expire?

Summary for Patent: 7,671,094